Vaxart (VXRT) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results
August 13, 2025 4:05 PM EDTReported positive topline data from Phase 1 clinical trial evaluating Companys second-generation oral norovirus vaccine constructs, supporting potential for improved protection against infection Â
Enrolled approximately 5,000 participants in COVID-19 Phase 2b trial prior to stop work order; Follow-up for all participants dosed, including 400-person sentinel cohort continues
Cash, cash equivalents and investments of $26.3 million as of June 30, 2025; Current runway into 2026
Conference call today at 4:30 p.m. ET
Live stockholder fireside chat scheduled on August 20, 2025 at 4:30 p.m. ET to answer frequently... More
